focus -WSS

focus

author：explore 2025-09-30 01:13:29 - browse：5

Micrograph of ulcerative colitis -- biotech coverage from STAT — Micrograph of chronic active ulcerative colitis in a biopsy specimen. Wikimedia Commons

Checkpoint inhibitors, drugs that unleash the immune system, have turned into blockbuster therapies that have transformed outcomes for some patients with deadly cancers. AltruBio, a Bay Area biotech, is betting it can help patients suffering from autoimmune and inflammatory diseases by taking the opposite tack: pumping the brakes on runaway immune responses.

The company on Tuesday announced that it has raised $225 million in a Series B venture round led by BVP Partners, with the biotech’s backers also including RA Capital Management, Cormorant Asset Management, and Soleus Capital. AltruBio plans to put that money toward advancing a drug that is already being tested in a mid-stage trial for ulcerative colitis, an increasingly competitive market in which a number of pharma companies have launched drugs.

It’s the latest example of intense investor interest in immunology-focused companies. Firms such as Paragon Therapeutics and Prometheus Laboratories have recently been at the center of financing mega-rounds, and Blackstone Life Sciences recently committed up to $300 million to launch Uniquity Bio, a company developing treatments for asthma and chronic obstructive pulmonary disease.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Novo Nordisk touts Wegovy study, but still struggling with supply

explore

WSS

After Optum profits sink, UnitedHealth makes changes

Doctors have an ethical obligation to be advocates

Megan Rapinoe shares emotional post following US Women's World Cup exit

FDA approves first blood sugar monitor without finger pricks

Thousands protest mob assault of women who were paraded naked in remote Indian border state

BMS, looking to build heart drug business, turns to AI for diagnosis

focus

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Dobbs anniversary: the lost opportunity of abortion as health care

Weekend shootings leave at least 6 dead, 20 others wounded in Chicago

Tori Bowie and the unacceptable rates of Black maternal death

Biogen’s boardroom scandal saddles CEO with first crisis

ChatGPT in medicine: STAT answers readers' burning questions

'The Earth is screaming at us': Gov. Inslee calls for climate action amid record heat

Affirmative action in medical school literally saved lives

Men with early prostate cancer can safely opt out of treatment

Peter Hotez and the public health issue of online harassment

Severe heat forecast: Where scorching temperatures will persist over the next week

hotspot

YouTube cracks down on misinformation on cancer treatment

BMS, looking to build heart drug business, turns to AI for diagnosis

Charges dismissed against white woman who spat on Black woman during protests in Connecticut

Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

Severe heat forecast: Where scorching temperatures will persist over the next week

Schizophrenia gene found to be linked to cells' energy dysfunction

entertainment

explore

focus

focus